Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | PHASE2 | RECRUITING | 90 | — | — | Jan 2, 2026 | Dec 15, 2028 | Feb 27, 2026 | 9 | United States |
ORR defined as the number of participants with a confirmed complete response (CR) or partial response during the study, as per RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| Stage 1 Participants | EXPERIMENTAL | 150 mg ONC206 BID TIW |
| Stage 2: Dose 1 | EXPERIMENTAL | Participants receiving ONC206 at dose (To be Determined \[TBD\] post stage 1). |
| Stage 2: Dose 2 | EXPERIMENTAL | Participants receiving ONC206 at dose (TBD post stage 1). |
| Name | Type | Description |
|---|---|---|
| ONC206 | DRUG | 150 mg BID TIW |
| ONC206: Dose 1 | DRUG | - |
| ONC206: Dose 2 | DRUG | - |
Inclusion criteria: 1. Has histologically confirmed pheochromocytoma or paraganglioma that is unresectable as determined by the Investigator. 2. Has failed, is not a candidate for, or has declined standard of care treatment for PCPG. There is no limit on the number of prior systemic therapies. 3. M...